METHODS AND RESULTS: This randomized, multicenter, prospective trial, called the Long
Drug-Eluting Stent (LONG-DES) V trial, compared the biodegradable
polymer-based biolimus A9-eluting
stent (
BES) and the durable
polymer-based
platinum chromium everolimus-eluting
stent (PtCr-EES) in 500 patients with long (≥ 25 mm) coronary lesions. The primary end point of the trial was in-segment late
luminal loss at the 9-month angiographic follow-up. The
BES and PtCr-EES groups had similar baseline characteristics, with a slightly shorter lesion length in the
BES group versus the PtCr-EES group (29.24 ± 12.17 versus 32.27 ± 13.84 mm; P = 0.016). In-segment late
luminal loss was comparable between the 2 groups at the 9-month angiographic follow-up (
BES, 0.14 ± 0.38 versus PtCr-EES, 0.11 ± 0.37 mm; difference, 0.031; 95% confidence interval, -0.053 to 0.091; P = 0.03 for a noninferiority margin of 0.11, P = 0.45 for superiority), as was in-
stent late
luminal loss (0.20 ± 0.41 versus 0.24 ± 0.38 mm; P = 0.29). The incidence of in-segment (6.1% versus 4.9%; P = 0.63) and in-
stent (3.7% versus 4.9%; P = 0.59) binary restenosis was also similar between the groups. There was no significant between-group difference in the rate of composite outcome of death,
myocardial infarction, and target vessel revascularization (41, 16.7% in
BES versus 42, 16.5% in PtCr-EES; P=0.94).
CONCLUSIONS: http://www.clinicaltrials.gov. Unique identifier: NCT01186120.